5Sridhar SS,Shepherd FA.Targeting angiogenesis:a review of angiogenesis inhibitors in the treatment of lung cancer[J].Lung Cancer,2003,42:S81-S91. 被引量：1
6Brock CS,Lee SM.Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer[J].Eur Respir J 2002,19:557-570. 被引量：1
7Johnson DH,Fehenbacher L,Novotny WF,et al.Randomized phase Ⅱ trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer[J].J Clin Oncol,2004,22(11):2184-2191. 被引量：1
8Shepherd FA,Sridhar SS.Angiogenesis inhibitors under study for the treatment of lung cancer[J].Lung Cancer,203,41:S63-S72. 被引量：1
9Herbst RS,Johnson DH,et al.Phase Ⅰ / Ⅱ trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer[J].Clin oncol,2005,23(11):2544-2555. 被引量：1
7Burger RA. Experience with bevacizumab in the magngement of epithelial ovarian cancer [J] . J Clin Oncol,2007, 25 (20) : 2902 -2903. 被引量：1
8Teng LS, Jin KT, He KF, et al. Advances in combination of antiangio- genic agents targeting VEGF - binding and conventional chemotherapy and radiation for cancer treatment [J] . J chin Med Assoc, 2010, 73 (6) : 281 -282. 被引量：1
9Degtrmenci M, Karaea B, Gorumlu G, et al. Eficacy and safety of bev- acizumals plua capectahine and irinoteean regimen for metastatic colorec- tal cancer [J]. Med Oncol, 2010, 27 (3) : 585 -591. 被引量：1
